Global Non-oncology Biopharmaceuticals Market Research Report 2023

Report ID: 1877049 | Published Date: Jan 2025 | No. of Page: 108 | Base Year: 2024 | Rating: 4.1 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
        1.2.2 Biologics
        1.2.3 Biosimilars
    1.3 Market by Application
        1.3.1 Global Non-oncology Biopharmaceuticals Market Share by Application: 2017 VS 2021 VS 2028
        1.3.2 Immunology
        1.3.3 Endocrinology
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Non-oncology Biopharmaceuticals Market Perspective (2017-2028)
    2.2 Non-oncology Biopharmaceuticals Growth Trends by Region
        2.2.1 Non-oncology Biopharmaceuticals Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Non-oncology Biopharmaceuticals Historic Market Size by Region (2017-2022)
        2.2.3 Non-oncology Biopharmaceuticals Forecasted Market Size by Region (2023-2028)
    2.3 Non-oncology Biopharmaceuticals Market Dynamics
        2.3.1 Non-oncology Biopharmaceuticals Industry Trends
        2.3.2 Non-oncology Biopharmaceuticals Market Drivers
        2.3.3 Non-oncology Biopharmaceuticals Market Challenges
        2.3.4 Non-oncology Biopharmaceuticals Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue
        3.1.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue (2017-2022)
        3.1.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by Players (2017-2022)
    3.2 Global Non-oncology Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Non-oncology Biopharmaceuticals Revenue
    3.4 Global Non-oncology Biopharmaceuticals Market Concentration Ratio
        3.4.1 Global Non-oncology Biopharmaceuticals Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Non-oncology Biopharmaceuticals Revenue in 2021
    3.5 Non-oncology Biopharmaceuticals Key Players Head office and Area Served
    3.6 Key Players Non-oncology Biopharmaceuticals Product Solution and Service
    3.7 Date of Enter into Non-oncology Biopharmaceuticals Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Non-oncology Biopharmaceuticals Breakdown Data by Type
    4.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Type (2017-2022)
    4.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2023-2028)
5 Non-oncology Biopharmaceuticals Breakdown Data by Application
    5.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Application (2017-2022)
    5.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Non-oncology Biopharmaceuticals Market Size (2017-2028)
    6.2 North America Non-oncology Biopharmaceuticals Market Size by Country (2017-2022)
    6.3 North America Non-oncology Biopharmaceuticals Market Size by Country (2023-2028)
    6.4 United States
    6.5 Canada
7 Europe
    7.1 Europe Non-oncology Biopharmaceuticals Market Size (2017-2028)
    7.2 Europe Non-oncology Biopharmaceuticals Market Size by Country (2017-2022)
    7.3 Europe Non-oncology Biopharmaceuticals Market Size by Country (2023-2028)
    7.4 Germany
    7.5 France
    7.6 U.K.
    7.7 Italy
    7.8 Russia
    7.9 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size (2017-2028)
    8.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Country (2017-2022)
    8.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Country (2023-2028)
    8.4 China
    8.5 Japan
    8.6 South Korea
    8.7 Southeast Asia
    8.8 India
    8.9 Australia
9 Latin America
    9.1 Latin America Non-oncology Biopharmaceuticals Market Size (2017-2028)
    9.2 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2017-2022)
    9.3 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2023-2028)
    9.4 Mexico
    9.5 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size (2017-2028)
    10.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2017-2022)
    10.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2023-2028)
    10.4 Turkey
    10.5 Saudi Arabia
    10.6 UAE
11 Key Players Profiles
    11.1 Roche
        11.1.1 Roche Company Detail
        11.1.2 Roche Business Overview
        11.1.3 Roche Non-oncology Biopharmaceuticals Introduction
        11.1.4 Roche Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
        11.1.5 Roche Recent Development
    11.2 Sanofi
        11.2.1 Sanofi Company Detail
        11.2.2 Sanofi Business Overview
        11.2.3 Sanofi Non-oncology Biopharmaceuticals Introduction
        11.2.4 Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
        11.2.5 Sanofi Recent Development
    11.3 Johnson & Johnson
        11.3.1 Johnson & Johnson Company Detail
        11.3.2 Johnson & Johnson Business Overview
        11.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Introduction
        11.3.4 Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
        11.3.5 Johnson & Johnson Recent Development
    11.4 Pfizer
        11.4.1 Pfizer Company Detail
        11.4.2 Pfizer Business Overview
        11.4.3 Pfizer Non-oncology Biopharmaceuticals Introduction
        11.4.4 Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
        11.4.5 Pfizer Recent Development
    11.5 Novo Nordisk
        11.5.1 Novo Nordisk Company Detail
        11.5.2 Novo Nordisk Business Overview
        11.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Introduction
        11.5.4 Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
        11.5.5 Novo Nordisk Recent Development
    11.6 Novartis
        11.6.1 Novartis Company Detail
        11.6.2 Novartis Business Overview
        11.6.3 Novartis Non-oncology Biopharmaceuticals Introduction
        11.6.4 Novartis Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
        11.6.5 Novartis Recent Development
    11.7 Merck
        11.7.1 Merck Company Detail
        11.7.2 Merck Business Overview
        11.7.3 Merck Non-oncology Biopharmaceuticals Introduction
        11.7.4 Merck Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
        11.7.5 Merck Recent Development
    11.8 Teva
        11.8.1 Teva Company Detail
        11.8.2 Teva Business Overview
        11.8.3 Teva Non-oncology Biopharmaceuticals Introduction
        11.8.4 Teva Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
        11.8.5 Teva Recent Development
    11.9 Eli Lilly
        11.9.1 Eli Lilly Company Detail
        11.9.2 Eli Lilly Business Overview
        11.9.3 Eli Lilly Non-oncology Biopharmaceuticals Introduction
        11.9.4 Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
        11.9.5 Eli Lilly Recent Development
    11.10 Bristol-Myers Squibb
        11.10.1 Bristol-Myers Squibb Company Detail
        11.10.2 Bristol-Myers Squibb Business Overview
        11.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Introduction
        11.10.4 Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
        11.10.5 Bristol-Myers Squibb Recent Development
    11.11 GlaxoSmithKline
        11.11.1 GlaxoSmithKline Company Detail
        11.11.2 GlaxoSmithKline Business Overview
        11.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Introduction
        11.11.4 GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
        11.11.5 GlaxoSmithKline Recent Development
    11.12 UCB Pharma
        11.12.1 UCB Pharma Company Detail
        11.12.2 UCB Pharma Business Overview
        11.12.3 UCB Pharma Non-oncology Biopharmaceuticals Introduction
        11.12.4 UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
        11.12.5 UCB Pharma Recent Development
    11.13 Amgen
        11.13.1 Amgen Company Detail
        11.13.2 Amgen Business Overview
        11.13.3 Amgen Non-oncology Biopharmaceuticals Introduction
        11.13.4 Amgen Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
        11.13.5 Amgen Recent Development
    11.14 AbbVie
        11.14.1 AbbVie Company Detail
        11.14.2 AbbVie Business Overview
        11.14.3 AbbVie Non-oncology Biopharmaceuticals Introduction
        11.14.4 AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
        11.14.5 AbbVie Recent Development
    11.15 Takeda
        11.15.1 Takeda Company Detail
        11.15.2 Takeda Business Overview
        11.15.3 Takeda Non-oncology Biopharmaceuticals Introduction
        11.15.4 Takeda Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
        11.15.5 Takeda Recent Development
    11.16 AstraZeneca
        11.16.1 AstraZeneca Company Detail
        11.16.2 AstraZeneca Business Overview
        11.16.3 AstraZeneca Non-oncology Biopharmaceuticals Introduction
        11.16.4 AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
        11.16.5 AstraZeneca Recent Development
    11.17 Mylan
        11.17.1 Mylan Company Detail
        11.17.2 Mylan Business Overview
        11.17.3 Mylan Non-oncology Biopharmaceuticals Introduction
        11.17.4 Mylan Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
        11.17.5 Mylan Recent Development
    11.18 LEO Pharma
        11.18.1 LEO Pharma Company Detail
        11.18.2 LEO Pharma Business Overview
        11.18.3 LEO Pharma Non-oncology Biopharmaceuticals Introduction
        11.18.4 LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
        11.18.5 LEO Pharma Recent Development
    11.19 Boehringer Ingelheim
        11.19.1 Boehringer Ingelheim Company Detail
        11.19.2 Boehringer Ingelheim Business Overview
        11.19.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Introduction
        11.19.4 Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
        11.19.5 Boehringer Ingelheim Recent Development
    11.20 Alexion Pharmaceuticals
        11.20.1 Alexion Pharmaceuticals Company Detail
        11.20.2 Alexion Pharmaceuticals Business Overview
        11.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Introduction
        11.20.4 Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
        11.20.5 Alexion Pharmaceuticals Recent Development
    11.21 Elusys Therapeutics
        11.21.1 Elusys Therapeutics Company Detail
        11.21.2 Elusys Therapeutics Business Overview
        11.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Introduction
        11.21.4 Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
        11.21.5 Elusys Therapeutics Recent Development
    11.22 Swedish Orphan Biovitrum
        11.22.1 Swedish Orphan Biovitrum Company Detail
        11.22.2 Swedish Orphan Biovitrum Business Overview
        11.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Introduction
        11.22.4 Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
        11.22.5 Swedish Orphan Biovitrum Recent Development
    11.23 Biogen
        11.23.1 Biogen Company Detail
        11.23.2 Biogen Business Overview
        11.23.3 Biogen Non-oncology Biopharmaceuticals Introduction
        11.23.4 Biogen Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
        11.23.5 Biogen Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Tables
    Table 1. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
    Table 2. Key Players of Biologics
    Table 3. Key Players of Biosimilars
    Table 4. Global Non-oncology Biopharmaceuticals Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
    Table 5. Global Non-oncology Biopharmaceuticals Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 6. Global Non-oncology Biopharmaceuticals Market Size by Region (2017-2022) & (US$ Million)
    Table 7. Global Non-oncology Biopharmaceuticals Market Share by Region (2017-2022)
    Table 8. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 9. Global Non-oncology Biopharmaceuticals Market Share by Region (2023-2028)
    Table 10. Non-oncology Biopharmaceuticals Market Trends
    Table 11. Non-oncology Biopharmaceuticals Market Drivers
    Table 12. Non-oncology Biopharmaceuticals Market Challenges
    Table 13. Non-oncology Biopharmaceuticals Market Restraints
    Table 14. Global Non-oncology Biopharmaceuticals Revenue by Players (2017-2022) & (US$ Million)
    Table 15. Global Non-oncology Biopharmaceuticals Market Share by Players (2017-2022)
    Table 16. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-oncology Biopharmaceuticals as of 2021)
    Table 17. Ranking of Global Top Non-oncology Biopharmaceuticals Companies by Revenue (US$ Million) in 2021
    Table 18. Global 5 Largest Players Market Share by Non-oncology Biopharmaceuticals Revenue (CR5 and HHI) & (2017-2022)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players Non-oncology Biopharmaceuticals Product Solution and Service
    Table 21. Date of Enter into Non-oncology Biopharmaceuticals Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Non-oncology Biopharmaceuticals Market Size by Type (2017-2022) & (US$ Million)
    Table 24. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2017-2022)
    Table 25. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 26. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2023-2028)
    Table 27. Global Non-oncology Biopharmaceuticals Market Size by Application (2017-2022) & (US$ Million)
    Table 28. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2017-2022)
    Table 29. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 30. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2023-2028)
    Table 31. North America Non-oncology Biopharmaceuticals Market Size by Country (2017-2022) & (US$ Million)
    Table 32. North America Non-oncology Biopharmaceuticals Market Size by Country (2023-2028) & (US$ Million)
    Table 33. Europe Non-oncology Biopharmaceuticals Market Size by Country (2017-2022) & (US$ Million)
    Table 34. Europe Non-oncology Biopharmaceuticals Market Size by Country (2023-2028) & (US$ Million)
    Table 35. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2017-2022) & (US$ Million)
    Table 36. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2023-2028) & (US$ Million)
    Table 37. Latin America Non-oncology Biopharmaceuticals Market Size by Country (2017-2022) & (US$ Million)
    Table 38. Latin America Non-oncology Biopharmaceuticals Market Size by Country (2023-2028) & (US$ Million)
    Table 39. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2017-2022) & (US$ Million)
    Table 40. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2023-2028) & (US$ Million)
    Table 41. Roche Company Detail
    Table 42. Roche Business Overview
    Table 43. Roche Non-oncology Biopharmaceuticals Product
    Table 44. Roche Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
    Table 45. Roche Recent Development
    Table 46. Sanofi Company Detail
    Table 47. Sanofi Business Overview
    Table 48. Sanofi Non-oncology Biopharmaceuticals Product
    Table 49. Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
    Table 50. Sanofi Recent Development
    Table 51. Johnson & Johnson Company Detail
    Table 52. Johnson & Johnson Business Overview
    Table 53. Johnson & Johnson Non-oncology Biopharmaceuticals Product
    Table 54. Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
    Table 55. Johnson & Johnson Recent Development
    Table 56. Pfizer Company Detail
    Table 57. Pfizer Business Overview
    Table 58. Pfizer Non-oncology Biopharmaceuticals Product
    Table 59. Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
    Table 60. Pfizer Recent Development
    Table 61. Novo Nordisk Company Detail
    Table 62. Novo Nordisk Business Overview
    Table 63. Novo Nordisk Non-oncology Biopharmaceuticals Product
    Table 64. Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
    Table 65. Novo Nordisk Recent Development
    Table 66. Novartis Company Detail
    Table 67. Novartis Business Overview
    Table 68. Novartis Non-oncology Biopharmaceuticals Product
    Table 69. Novartis Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
    Table 70. Novartis Recent Development
    Table 71. Merck Company Detail
    Table 72. Merck Business Overview
    Table 73. Merck Non-oncology Biopharmaceuticals Product
    Table 74. Merck Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
    Table 75. Merck Recent Development
    Table 76. Teva Company Detail
    Table 77. Teva Business Overview
    Table 78. Teva Non-oncology Biopharmaceuticals Product
    Table 79. Teva Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
    Table 80. Teva Recent Development
    Table 81. Eli Lilly Company Detail
    Table 82. Eli Lilly Business Overview
    Table 83. Eli Lilly Non-oncology Biopharmaceuticals Product
    Table 84. Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
    Table 85. Eli Lilly Recent Development
    Table 86. Bristol-Myers Squibb Company Detail
    Table 87. Bristol-Myers Squibb Business Overview
    Table 88. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product
    Table 89. Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
    Table 90. Bristol-Myers Squibb Recent Development
    Table 91. GlaxoSmithKline Company Detail
    Table 92. GlaxoSmithKline Business Overview
    Table 93. GlaxoSmithKline Non-oncology BiopharmaceuticalsProduct
    Table 94. GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
    Table 95. GlaxoSmithKline Recent Development
    Table 96. UCB Pharma Company Detail
    Table 97. UCB Pharma Business Overview
    Table 98. UCB Pharma Non-oncology BiopharmaceuticalsProduct
    Table 99. UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
    Table 100. UCB Pharma Recent Development
    Table 101. Amgen Company Detail
    Table 102. Amgen Business Overview
    Table 103. Amgen Non-oncology BiopharmaceuticalsProduct
    Table 104. Amgen Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
    Table 105. Amgen Recent Development
    Table 106. AbbVie Company Detail
    Table 107. AbbVie Business Overview
    Table 108. AbbVie Non-oncology BiopharmaceuticalsProduct
    Table 109. AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
    Table 110. AbbVie Recent Development
    Table 111. Takeda Company Detail
    Table 112. Takeda Business Overview
    Table 113. Takeda Non-oncology BiopharmaceuticalsProduct
    Table 114. Takeda Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
    Table 115. Takeda Recent Development
    Table 116. AstraZeneca Company Detail
    Table 117. AstraZeneca Business Overview
    Table 118. AstraZeneca Non-oncology BiopharmaceuticalsProduct
    Table 119. AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
    Table 120. AstraZeneca Recent Development
    Table 121. Mylan Company Detail
    Table 122. Mylan Business Overview
    Table 123. Mylan Non-oncology BiopharmaceuticalsProduct
    Table 124. Mylan Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
    Table 125. Mylan Recent Development
    Table 126. LEO Pharma Company Detail
    Table 127. LEO Pharma Business Overview
    Table 128. LEO Pharma Non-oncology BiopharmaceuticalsProduct
    Table 129. LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
    Table 130. LEO Pharma Recent Development
    Table 131. Boehringer Ingelheim Company Detail
    Table 132. Boehringer Ingelheim Business Overview
    Table 133. Boehringer Ingelheim Non-oncology BiopharmaceuticalsProduct
    Table 134. Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
    Table 135. Boehringer Ingelheim Recent Development
    Table 136. Alexion Pharmaceuticals Company Detail
    Table 137. Alexion Pharmaceuticals Business Overview
    Table 138. Alexion Pharmaceuticals Non-oncology BiopharmaceuticalsProduct
    Table 139. Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
    Table 140. Alexion Pharmaceuticals Recent Development
    Table 141. Elusys Therapeutics Company Detail
    Table 142. Elusys Therapeutics Business Overview
    Table 143. Elusys Therapeutics Non-oncology BiopharmaceuticalsProduct
    Table 144. Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
    Table 145. Elusys Therapeutics Recent Development
    Table 146. Swedish Orphan Biovitrum Company Detail
    Table 147. Swedish Orphan Biovitrum Business Overview
    Table 148. Swedish Orphan Biovitrum Non-oncology BiopharmaceuticalsProduct
    Table 149. Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
    Table 150. Swedish Orphan Biovitrum Recent Development
    Table 151. Biogen Company Detail
    Table 152. Biogen Business Overview
    Table 153. Biogen Non-oncology BiopharmaceuticalsProduct
    Table 154. Biogen Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
    Table 155. Biogen Recent Development
    Table 156. Research Programs/Design for This Report
    Table 157. Key Data Information from Secondary Sources
    Table 158. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Non-oncology Biopharmaceuticals Market Share by Type: 2021 VS 2028
    Figure 2. Biologics Features
    Figure 3. Biosimilars Features
    Figure 4. Global Non-oncology Biopharmaceuticals Market Share by Application in 2021 & 2028
    Figure 5. Immunology Case Studies
    Figure 6. Endocrinology Case Studies
    Figure 7. Others Case Studies
    Figure 8. Non-oncology Biopharmaceuticals Report Years Considered
    Figure 9. Global Non-oncology Biopharmaceuticals Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 10. Global Non-oncology Biopharmaceuticals Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 11. Global Non-oncology Biopharmaceuticals Market Share by Region: 2021 VS 2028
    Figure 12. Global Non-oncology Biopharmaceuticals Market Share by Players in 2021
    Figure 13. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-oncology Biopharmaceuticals as of 2021)
    Figure 14. The Top 10 and 5 Players Market Share by Non-oncology Biopharmaceuticals Revenue in 2021
    Figure 15. North America Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 16. North America Non-oncology Biopharmaceuticals Market Share by Country (2017-2028)
    Figure 17. United States Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 18. Canada Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 19. Europe Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 20. Europe Non-oncology Biopharmaceuticals Market Share by Country (2017-2028)
    Figure 21. Germany Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 22. France Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. U.K. Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. Italy Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. Russia Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. Nordic Countries Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. Asia-Pacific Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. Asia-Pacific Non-oncology Biopharmaceuticals Market Share by Region (2017-2028)
    Figure 29. China Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Japan Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. South Korea Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Southeast Asia Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. India Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Australia Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Latin America Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Latin America Non-oncology Biopharmaceuticals Market Share by Country (2017-2028)
    Figure 37. Mexico Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Brazil Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Middle East & Africa Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Middle East & Africa Non-oncology Biopharmaceuticals Market Share by Country (2017-2028)
    Figure 41. Turkey Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Saudi Arabia Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Roche Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
    Figure 44. Sanofi Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
    Figure 45. Johnson & Johnson Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
    Figure 46. Pfizer Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
    Figure 47. Novo Nordisk Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
    Figure 48. Novartis Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
    Figure 49. Merck Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
    Figure 50. Teva Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
    Figure 51. Eli Lilly Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
    Figure 52. Bristol-Myers Squibb Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
    Figure 53. GlaxoSmithKline Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
    Figure 54. UCB Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
    Figure 55. Amgen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
    Figure 56. AbbVie Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
    Figure 57. Takeda Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
    Figure 58. AstraZeneca Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
    Figure 59. Mylan Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
    Figure 60. LEO Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
    Figure 61. Boehringer Ingelheim Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
    Figure 62. Alexion Pharmaceuticals Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
    Figure 63. Elusys Therapeutics Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
    Figure 64. Swedish Orphan Biovitrum Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
    Figure 65. Biogen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
    Figure 66. Bottom-up and Top-down Approaches for This Report
    Figure 67. Data Triangulation
    Figure 68. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Roche
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Novartis
Merck
Teva
Eli Lilly
Bristol-Myers Squibb
GlaxoSmithKline
UCB Pharma
Amgen
AbbVie
Takeda
AstraZeneca
Mylan
LEO Pharma
Boehringer Ingelheim
Alexion Pharmaceuticals
Elusys Therapeutics
Swedish Orphan Biovitrum
Biogen
Frequently Asked Questions
Non-oncology Biopharmaceuticals report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Non-oncology Biopharmaceuticals report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Non-oncology Biopharmaceuticals report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Beta Glucan Products

The research report includes specific segments by region (country), by company, by Type and by Ap ... Read More